Figure 2. Combination αCTLA-4/α4-1BB therapy promotes high effector to regulatory T-cell ratios in the tumor.
Mice were challenged with 1.5×105 B16-BL6, treated with FVAX and the indicated antibody on days 3,6 and 9, and sacrificed on day 15. Percent of CD45+ tumor infiltrating lymphocytes of A) CD8+ T-cells, B) CD4+ effector (Teff) and C) regulatory (Treg) cells is shown. The ratios of D) CD8+ T-cells to Tregs and E) CD4+ Teff to Treg are shown. Values shown are for individually analyzed mice and are the sum of 5 independent experiments with 5–15 mice per group. The ratios of F) CD8+ T-cells to Tregs and G) CD4+ Teff to Treg are shown at Day 25 for individual mice from 2 independent experiments. Student's t-tests were performed to determine statistical significance between samples (* - p≤0.05, ** - p≤0.01, ***-p<0.001).